Exploring KCTD Proteins in Childhood Leukemias
Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias
IRCCS SYNLAB SDN · NCT05729178
This study looks at how KCTD proteins might be linked to childhood leukemia by examining bone marrow samples from kids with B-ALL and T-ALL to help improve diagnosis and treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 1 Year to 18 Years |
| Sex | All |
| Sponsor | IRCCS SYNLAB SDN (other) |
| Locations | 1 site (Naples) |
| Trial ID | NCT05729178 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the role of KCTD proteins in childhood acute lymphoblastic leukemia (ALL) by analyzing bone marrow samples from pediatric patients diagnosed with B-ALL and T-ALL. The research aims to identify novel biomarkers associated with these leukemias, focusing on the deregulation of KCTD proteins, which have not been previously studied in this context. The study is conducted in collaboration with AORN Santobono-Pausilipon pediatric oncological hospital, aiming to enhance diagnostics and patient management for affected children.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 1-18 years diagnosed with B-ALL or T-ALL.
Not a fit: Patients outside the age range of 1-18 years or those who refuse to participate will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of new biomarkers that improve the diagnosis and management of childhood acute lymphoblastic leukemia.
How similar studies have performed: While KCTD proteins have not been previously studied in ALL, the approach of identifying novel biomarkers in leukemia has shown promise in other studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 1-18 years of both sexes diagnosed with B- ALL and T-ALL; * Patients who will have signed the informed consent Exclusion Criteria: * Patients who refuse to participate in the study; * Patients who do not fall within the age range mentioned above
Where this trial is running
Naples
- IRCCS Synlab SDN — Naples, Italy (RECRUITING)
Study contacts
- Study coordinator: Laura Pierri, MSC
- Email: direzionescientifica.irccssdn@synlab.it
- Phone: 0812408470
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Childhood Acute Lymphoblastic Leukemia